These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 33421620)

  • 1. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
    Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
    Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 in epigenetics studies of health and disease.
    Sar P; Dalai S
    Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing.
    Majchrzak-Celińska A; Warych A; Szoszkiewicz M
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic editing: Dissecting chromatin function in context.
    Policarpi C; Dabin J; Hackett JA
    Bioessays; 2021 May; 43(5):e2000316. PubMed ID: 33724509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.
    Goell JH; Hilton IB
    Trends Biotechnol; 2021 Jul; 39(7):678-691. PubMed ID: 33972106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer.
    Chakravarti R; Lenka SK; Gautam A; Singh R; Ravichandiran V; Roy S; Ghosh D
    Curr Drug Targets; 2022; 23(8):836-853. PubMed ID: 35078394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing the Epigenome to Tackle Brain Disorders.
    Liu XS; Jaenisch R
    Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editing the Epigenome: Reshaping the Genomic Landscape.
    Holtzman L; Gersbach CA
    Annu Rev Genomics Hum Genet; 2018 Aug; 19():43-71. PubMed ID: 29852072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for Allele-Specific Epigenome Editing Using CRISPR/dCas9.
    Rajaram N; Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2024; 2842():179-192. PubMed ID: 39012596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenome editing technologies for discovery and medicine.
    McCutcheon SR; Rohm D; Iglesias N; Gersbach CA
    Nat Biotechnol; 2024 Aug; 42(8):1199-1217. PubMed ID: 39075148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances of epigenetic editing.
    Gjaltema RAF; Rots MG
    Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
    Rahman MM; Tollefsbol TO
    Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in CRISPR-Cas systems for epigenetics.
    Ilyas M; Shah Q; Gul A; Ibrahim H; Fatima R; Babar MM; Rajadas J
    Prog Mol Biol Transl Sci; 2024; 208():185-209. PubMed ID: 39266182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
    Guerra-Resendez RS; Hilton IB
    Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on CRISPR/Cas-based epigenetic regulation in plants.
    Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
    Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.